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Cutaneous B-cell lymphomas (CBCL) are rare heterogeneous neoplastic diseases composing about 22.5% of all cutaneous
lymphomas. 'ese diseases can be divided into primary and secondary cutaneous variants with primary cutaneous B-cell
lymphoma (PCBCL) divided into three distinct entities including primary cutaneous marginal zone lymphoma, primary cu-
taneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). Secondary
cutaneous diffuse large B-cell lymphoma (CDLBCL) and PCDLBCL, LT are more aggressive neoplasms compared to the
aforementioned CBCL with survival rates of 37% and 50% after 5 years, respectively. CDLBCL can present as cutaneous or
subcutaneous nodules, papular lesions, or indurated plaques. Here, we present a case of CDLBCL of an 88-year-old female that
was mistaken for lower extremity cellulitis with phlegmon. Our patient failed two courses of antibiotic therapy as an outpatient
and received a third as an inpatient before a cutaneous biopsy clinched the diagnosis.
1. Introduction
Diffuse large B-cell lymphoma (DLBCL) comprises one-
third of all non-Hodgkin’s lymphomas (NHL). DLBCL is
composed of multiple diverse neoplasms involving both
primary extranodal and nodal types. Epidemiologically,
DLBCL is most common in Caucasians and men and the
incidence increasing with older age. Of the extranodal
subtypes, gastrointestinal, head and neck, and skin and soft
tissue comprise the majority of primary sites.'e distinction
between primary cutaneous diffuse large B-cell lymphoma
(PCDLBCL) and DLBCL with secondary cutaneous in-
volvement is based on extracutaneous involvement at the
time of diagnosis. PCDLBCL can metastasize to extrac-
utaneous sites, as is seen in 40% of patients with PCDLBCL,
leg type (PCDLBCL, LT), often making it difficult to es-
tablish a primary cutaneous diagnosis [1]. Prognosis of
DLBCL is variable based on subtype with 5-year survival
rates ranging from 30–80%; however, prognosis of sec-
ondary cutaneous DLBCL and PCDLBCL, LT are both poor
with 5-year disease specific survival rates at 37% and 50%,
respectively [2]. It is therefore critical to diagnose cutaneous
diffuse large B-cell lymphoma (CDLBCL) early on in its
pathogenesis [3].
2. Case
An 88-year-old woman with a history of type II diabetes
mellitus, chronic deep venous thrombosis (DVT) of right
femoral vein, and atrial fibrillation on coumadin presented
to her primary care physician (PCP) with right lower leg
extremity swelling, erythema, and pain. A week prior to
presentation, there was development of a sore on her right
posterior ankle that began to crust over. 'e patient’s leg
became increasingly edematous, painful, warm, and ery-
thematous throughout the week. Her primary care physician
prescribed cephalexin for 10 days followed by doxycycline
for four days. She continued to have progression of her
symptoms while on these antibiotics (Figure 1(a)). She then
developed intermittent purulent drainage from the sore
behind the ankle concurrently with severe pain radiating
down the leg (Figure 1(c)). She was then hospitalized and
assessed for a deep soft tissue infection, abscess, and deep
vein thrombosis. Cefazolin was given with subsequent
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improvement in the degree of erythema, though she con-
tinued to endorse significant pain. As the erythema receded
to the mid-shin, the patient had persistent scattered papules
and macules along the upper calf (Figure 1(b)). Blood
cultures were negative and over the course of her illness, she
remained afebrile without night sweats or chills. Laboratory
workup revealed an elevated CRP (11.4mg/L), which was felt
to be secondary to an active infection. At presentation, a
complete blood count with differential was within normal
limits (white blood cell count 6.0 thousand cells/μL). On
hospital day 3, she underwent a CT lower extremity with
contrast due to continued pain, which was significant for
diffuse heterogeneity in the calf muscle, notably a
1.8×1.3× 3.8 cm lesion in the gastrocnemius without evi-
dence of a drainable fluid collection or air within the soft
tissue. 'e leading differential at this time was myositis with
phlegmon leading to persistent pain and continued ery-
thema and edema. She proceeded to have a skin biopsy for
culture and histochemistry, which displayed an atypical
mononuclear infiltrate, and previous imaging was reinter-
preted as possible malignancy. Immunohistochemical
staining done was negative for CD10 and positive for
CD20, MUM1, BCL-2, and BCL-6 consistent with primary
cutaneous diffuse large B-cell lymphoma, leg type; how-
ever, secondary cutaneous nongerminal DLBCL was not
ruled out.
Of note, during hospitalization LDH was found to be
elevated to 506U/L. Following discharge, there was an
overall increase in LDH value with slight fluctuations from
694U/L to 616U/L and ultimately reaching a maximum
value of 737U/L when last assessed. Patient’s complete
blood count remained unremarkable throughout hospi-
talization besides for mild normocytic anemia (hemoglobin
approximately 11.5 g/dL). CT abdomen and pelvis with
contrast revealed an enlarged right inguinal lymph node
1.6 ×1.8 cm. 'ere was no intra-abdominal or retroperi-
toneal lymphadenopathy. CT chest with contrast did not
show new nodules nor did it show mediastinal or hilar
adenopathy. PET/CT scan performed 2 weeks after dis-
charge and 1 month following presentation showed ex-
tensive intensely FDG-avid muscular, soft tissue, and
dermal lymphomatous involvement in lower extremities,
right greater than left. 'ere were additionally discrete soft
tissue nodules and lymph nodes in the lower extremities,
left buttock, right inguinal region, and right external iliac.
'e patient was diagnosed with advanced stage IV non-
germinal DLBCL. 'e patient was later started on ritux-
imab to polychemotherapy (R-CHOP) but was transitioned
to hospice care after developing sepsis, DIC, and a new
DVT.
3. Discussion
DLBCL typically presents in males in the 7th decade of life
with a median age of 64 years old, though DLBCL can
present at any age, accounting for 20% of NHL in children
under 14 years old [4]. In a study comparing cutaneous
lymphomas, it was found that 22.5% of cases of cutaneous
lymphoma were of B-cell lymphomas with 44.4% consti-
tuting primary cutaneous disease [5]. Primary cutaneous
lymphomas are divided into 3 subtypes according to the
2008 World Health Organization-European Organization
for Research and Treatment of Cancer (EORTC) including
primary cutaneous marginal zone lymphoma, primary cu-
taneous follicle center lymphoma, and primary cutaneous
diffuse large B-cell lymphoma, leg type [6].
PCDLBCL, LT in contrast to the aforementioned CBCL
and other DLBCL commonly affects females and has a poor
prognosis. 'e median age for PCDLBCL, LT at presen-
tation is 70–82 years old [1, 6]. Most cases involve the lower
legs; however, around 10% of cases can involve other
cutaneous sites and extracutaneous dissemination is
common. Most cases are MUM-1/IRF-4, BCL-2, and BCL-
6 positive as was seen with our patient [6].
(a) (b) (c)
Figure 1: (a) Photograph of right lower extremity anterior view taken 4 days prior to admission following 10 days of cephalexin therapy.
(b) Photograph of bilateral lower extremities anterior view taken on hospital day 4; on day 4 of cefazolin therapy prior to biopsy and
diagnosis. (c) Photograph taken on hospital day 10 after 3 failed treatments of antibiotic therapy and after diagnosis of DLBCL.
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A study assessing presentations of DLBCL secondary
cutaneous disease found that secondary cutaneous disease
most commonly involves the legs and most frequently
presents as cutaneous nodules, but in 16% of cases, it
presents with papular lesions, as was seen with our patient
[3]. 'ere is scarce literature detailing the course of sec-
ondary cutaneous DLBCL.'e prognosis and clinical course
is much more aggressive in secondary cutaneous DLBCL
compared to the indolent PCBCL in what has been reported.
A patient diagnosed with secondary cutaneous DLBCL
qualifies for stage IV disease per Ann Arbour staging giving
an unfavorable diagnosis to those with the disease. Other
unfavorable factors include age> 60, ECOG> 2, involve-
ment of more than 2 extranodal sites, and elevated LDH [4].
Our patient’s case was complex due to her comorbidities,
partial response to antibiotic therapy, and lack of consti-
tutional symptoms which led to a difficult diagnosis. Ini-
tially, we believed her underlying type II diabetes mellitus,
peripheral vascular diseases, and chronic lower extremity
edema predisposed her to an infectious etiology. 'erefore,
we continued to treat as if this patient had a cellulitis with
phlegmon in the setting of supportive radiographic evidence.
Ultimately, minimal improvement in symptoms led to a
biopsy leading to a diagnosis of CDLBCL. 'is case high-
lights the difficulty in diagnosing patients with CDLBCL
given the rarity and unusual presentation of this illness. At
the time of diagnosis, our patient had extracutaneous in-
volvement including the gastrocnemius and, on PET-scan,
surrounding lymph nodes therefore limiting our confidence
in diagnosing primary cutaneous disease.
Survival rates for CDLBCL have improved with the
addition of rituximab to polychemotherapy (R-CHOP);
however, up to 40% of disease becomes refractory to this
treatment or relapses [4]. Unfortunately, our patient was
unable to complete R-CHOP therapy after developing DIC,
sepsis, and a new DVT. Given the late age of onset of this
disease, aggressive polychemotherapy may not be feasible,
and therefore more targeted or localized therapies are re-
quired. Exciting developments in CD19 targeted chimeric
antigen receptor T-cell (CAR-T) therapy show promise in
treating B-cell malignancies expressing the CD19 trans-
membrane glycoprotein, as is seen in many DLBCL.
However, these treatments are costly and can have conse-
quential side effects such as cytokine release syndrome and
neurotoxicity [7]. Gaps do remain in our understanding of
this disease process, specifically in secondary cutaneous
disease. Research must focus on understanding the micro-
environment of this neoplasm as a means of better targeting
the cells driving this process.
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